ALK and non-small cell lung carcinoma: NAUTIKA1 (or ML41591, NCT04302025) is an umbrella, phase 2, multicenter, open-label, and non-randomized trial enrolling patients with resectable stage II, IIIA, or selected IIIB NSCLC with ALK, ROS1, NTRK, and BRAFV600E alterations [78].